Lipase variants for pharmaceutical use
US9029115B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 16, 2012 |
| Grant date | May 12, 2015 |
| Priority date | — |
| Expiry date | Feb 4, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.